MedTrace Logo

Evaluation of the Capacity of a Camera to Identify Signs of Arteriosclerosis in Retinal Arterioles

NCT02849405 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-28

No results posted yet for this study

Summary

Arteriosclerosis is a degenerative and dysmetabolic disease of the arterial walls. It is known to be the principal cause of coronary artery disease (CAD). Arteriosclerosis has an impact on the entire vascularization including the microvascularization. The retina is a nervous tissue that is supported by microvascularization. Therefore, systemic diseases that affect the nervous or the cardiovascular system are susceptible to have manifestations in the retina. Retinal signs associated to the risks to develop CAD (qualitative appreciation; diameter and appearance of arterioles) have been suggested. A quantitative approach would strengthen the interpretation of these evaluations.

The Metabolic Hyperspectral Retinal Camera (MHRC) - the experimental instrument - has the capacity to identify and quantify a variety of biomolecules specific to the retina and the optic nerve.

The purpose of this pilot study is to determine if the MHRC has the capacity to detect a specific hyperspectral signature in the retinal arterioles of subjects suffering from arteriosclerosis.

Conditions

  • Arteriosclerosis

Interventions

DEVICE

MHRC: Metabolic Hyperspectral Retinal Camera

Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.

Sponsors & Collaborators

  • Montreal Heart Institute

    collaborator OTHER

  • Polytechnique Montréal

    collaborator UNKNOWN

  • Jean-Claude Tardif

    lead OTHER

Principal Investigators

  • Jean-Claude Tardif, MD · Montreal Heart Insitute

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-21
Primary Completion
2021-09-16
Completion
2021-09-16

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849405 on ClinicalTrials.gov